Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic treatment versus no antibiotic treatment after catheter removal for low-risk coagulase-negative staphylococcal central venous catheter-related bloodstream infection
2007-007062-38Phase 4Active
- Sponsor
- Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón
- Start
- Jan 2008
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vancomycin, cloxacillin and linezolid in catheter-associated bloodstream infection (CRBSI) (2 arms), sponsored by Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón. Primary endpoint: Clinical response within the first 72 hours after inclusion. Started Jan 2008; status: active.
02
Drugs
vancomycincloxacillinlinezolid
03
Conditions
catheter-associated bloodstream infection (CRBSI)
Beyond the preview
Go deeper on 2007-007062-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007062-38.